Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Part of paid clinical trials in Washington D.C., District of Columbia.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT01811212
- Phase
- PHASE2
- Status
- Completed
Conditions
- Poorly Differentiated Thyroid Gland Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Stage I Thyroid Gland Follicular Carcinoma
- Stage I Thyroid Gland Papillary Carcinoma
- Stage II Thyroid Gland Follicular Carcinoma
- Stage II Thyroid Gland Papillary Carcinoma
- Stage III Thyroid Gland Follicular Carcinoma
- Stage III Thyroid Gland Papillary Carcinoma
- Stage IVA Thyroid Gland Follicular Carcinoma
- Stage IVA Thyroid Gland Papillary Carcinoma
- Stage IVB Thyroid Gland Follicular Carcinoma
- Stage IVB Thyroid Gland Papillary Carcinoma
- Stage IVC Thyroid Gland Follicular Carcinoma
- Stage IVC Thyroid Gland Papillary Carcinoma
- Tall Cell Variant Thyroid Gland Papillary Carcinoma
- Thyroid Gland Oncocytic Follicular Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cabozantinib S-malate — DRUGGiven PO
- Laboratory Biomarker Analysis — OTHERCorrelative studies
Study Details
This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor.
Key Dates
- Start date
- May 8, 2013
- Status verified
- Mar 2018
- Primary completion
- Jul 13, 2015
- Completion
- Oct 9, 2017
Study Design
- Enrollment
- 25 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (cabozantinib-s-malate)Patients receive cabozantinib-s-malate PO daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Primary Outcome Measure
Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 [ Time Frame: Up to 6 months ]
Locations (7)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| MedStar Georgetown University Hospital | Washington D.C. | District of Columbia | 20007 | - |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224-9980 | - |
| University of Chicago Comprehensive Cancer Center | Chicago | Illinois | 60637 | - |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | - |
| Mayo Clinic | Rochester | Minnesota | 55905 | - |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | - |
| M D Anderson Cancer Center | Houston | Texas | 77030 | - |
Find similar trials in Washington D.C., DC
By research site
MedStar Georgetown University Hospital· Washington D.C., DCMayo Clinic in Florida· Jacksonville, FLUniversity of Chicago Comprehensive Cancer Center· Chicago, ILMassachusetts General Hospital Cancer Center· Boston, MAMayo Clinic· Rochester, MNOhio State University Comprehensive Cancer Center· Columbus, OH